322474-21-5

Basic information

• Product Name: N,N'-bis-Boc-S-methyl-isothiourea
• Synonyms: N,N'-bis-Boc-S-methyl-isothiourea
• CAS NO: 322474-21-5
• Molecular Weight: 290.384
• Mol File: 322474-21-5.mol
• Article Data: 26

Chemical Properties

• CAS DataBase Reference: N,N'-bis-Boc-S-methyl-isothiourea(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-bis-Boc-S-methyl-isothiourea(322474-21-5)
• EPA Substance Registry System: N,N'-bis-Boc-S-methyl-isothiourea(322474-21-5)

Safety Data

• Hazardous Substances Data: 322474-21-5(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 14527-26-5 2-methylisothiourea sulphate 
• 2986-19-8 carbamimidothioic acid methyl ester 
• 867-44-7 S-Methylisothiourea sulfate 
• 147895-43-0 S-methylisothiourea hemisulphate 
• 34619-03-9 tert-butyldicarbonate 
• 4338-95-8 S-methylthiouronium iodide 
• 861333-51-9 S-methyl isothiouronium sulphate 

Downstream Products

• 132502-56-8 N-4-benzyloxycarbonylaminobutyl-N,N'-di-tert-butoxycarbonylguanidine 
• 158478-70-7 N,N′-bis(tert-butoxycarbonyl)-N′′-cyclohexylguanidine 
• 215050-11-6 N,N’‘-bis(tert-butoxycarbonyl)-N’-(2-hydroxyethyl)guanidine 
• 160677-41-8 <(6-aminohexyl)carbonimidoyl>bis-carbamic acid, bis(1,1-dimethylethyl)ester 
• 203258-18-8 N,N'-bis(tert-butoxycarbonyl)-N''-(3-(hydroxymethyl)phenyl)guanidine 
• 239482-65-6 1,3'-bis(tert-butoxycarbonyl)-1-(4-chlorobenzyl)-2-methyl-2-thiopseudourea 
• 239482-87-2 N,N-bis(tert-butoxycarbonyl)-N''-(4-chlorobenzyl)-N''-(4-pyrrolidin-1-ylbutyl)guanidine 
• 239482-90-7 N,N'-bis(tert-butyoxycarbonyl)-N''-(4-chlorobenzyl)-N''-(5-pyrrolidin-1-yl-pentyl)-guanidine 
• 264198-14-3 C₃₂H₄₈N₆O₁₁ 
• 264198-19-8 C₃₂H₄₈N₆O₁₁ 
• 264198-06-3 (2S,2'R,5'R,1''S)-3-[5'-(1''-Benzyloxycarbonylamino-4''-[N²''',N³'''-bis(tert-butoxycarbonyl)guanidino]butyl)tetrahydrofuran-2'-carbamoyl]-2-benzyloxycarbonylamino methyl propionate 
• 313950-09-3 tert-butyl 2-aza-3-[(tert-butoxy)carbonylamino]-3-{[2-(ethoxycarbonyl)-5-phenylpyrrol-3-yl]amino}prop-2-enoate 
• 655251-01-7 C₁₉H₂₉N₃O₅ 
• 347190-87-8 2,5-bis(4-N,N'-di-BOCguanidinophenyl)furan 

Relevant articles and documents

Leonurine derivative and application thereof in preparing medicine for preventing or treating ischemic cerebrovascular diseases

The invention provides a leonurine derivative and application of the leonurine derivative in preparation of a medicine for preventing or treating ischemic cerebrovascular diseases. The leonurine derivative has a structure as shown in a general formula (I), wherein X is selected from O or NH; Y is selected from any one of natural amino acid, substituted amino acid or amino alcohol; Z is selected from H, proline and any substituted proline. Pharmacological experiments prove that the leonurine derivative provided by the invention has the effects of neuroprotection, cerebral infarction area reduction and animal neurobehavioral scoring, and is good in safety, so that the leonurine derivative has important significance for developing novel medicines for preventing or treating ischemic cerebrovascular diseases.

Synthesis of Nω,Νω–di-Boc-3-guanidylpropanal - An Important Reagent for Synthesis of Aza-Arg Precursors

-

Design and synthesis of novel SCM-198 analogs as cardioprotective agents: Structure-activity relationship studies and biological evaluations

SCM-198 (Leonurine) has attracted great attention due to its cardioprotective effects in myocardial infarction (MI). However, no systematic modifications and structure-activity relationship (SAR) studies could be traced so far. In this study, 35 analogs of SCM-198 were designed, synthesized and their cardioprotective effects were evaluated. The cell viability assay on cardiomyocyte cell line H9c2 challenged with H2O2 showed that several analogs exhibited more potent cytoprotective effects than SCM-198 at 1 μM and 10 μM concentrations. LDH release level in cells treated with 1 μM 14o was comparable with cells treated with 10 μM SCM-198. Results of Bcl-2 expression and caspase-3 activation accordingly indicated higher protective activity of 14o than SCM-198. Moreover, in a mouse model of MI, the mice pretreated with 14o had much lower infarct size compared with that of SCM-198. The mechanism study suggested that 14o improved cardiac morphology and reduced apoptosis of cardiomyocytes in the border zone of infarction, as proved by H&E and TUNEL staining.